News
and UCL’s world-leading research capabilities are supported by ViroCell’s delivery of a high quality, high yield lentiviral vector to advance UCL’s Phase I CARPALL (cohort 4) clinical trial ...
UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia London, UK and New York, US, 17 ...
UCL leveraged ViroCell’s expertise in lentiviral vector manufacturing for an innovative CAR T-cell therapy for the treatment of paediatric acute lymphoblastic leukaemia ViroCell Biologics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results